Advantage Alpha Capital Partners LP Veracyte, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Veracyte, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 25,066 shares of VCYT stock, worth $1.03 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
25,066
Previous 45,729
45.19%
Holding current value
$1.03 Million
Previous $990,000
13.94%
% of portfolio
0.2%
Previous 0.22%
Shares
4 transactions
Others Institutions Holding VCYT
# of Institutions
307Shares Held
81.7MCall Options Held
134KPut Options Held
13.3K-
Black Rock Inc. New York, NY7.79MShares$321 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.75MShares$319 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI5.02MShares$207 Million0.27% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.92MShares$203 Million1.59% of portfolio
-
Wellington Management Group LLP Boston, MA4.23MShares$174 Million0.03% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $2.95B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...